LAVAL, QC, Jan. 5 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced that it will host a conference call on Tuesday, January 6, 2009 at
8:30 a.m. (ET) to discuss the U.S. Food and Drug Administration's (FDA)
approval of its once-daily formulation of tramadol, RYZOLT(TM). Joining Mr.
James R. Howard-Tripp, President and Chief Executive Officer of Labopharm
Inc., will be John H. Stewart, President and Chief Executive Officer of Purdue
Pharma L.P., Labopharm's marketing partner for RYZOLT in the United States.
To access the conference call by telephone, dial 416-644-3414 or
1-800-733-7560. Please connect approximately 15 minutes prior to the beginning
of the call to ensure participation. The conference call will be archived for
replay until Tuesday, January 13, 2009 at midnight. To access the archived
conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation
number 21293677 followed by the number sign.
A live audio webcast of the conference call will be available at
www.labopharm.com. Please connect at least 15 minutes prior to the conference
call to ensure adequate time for any software download that may be required to
join the webcast. The webcast will be archived at the above web site for 30
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
being commercially launched in key markets globally and its second product, a
novel formulation of trazodone for the treatment of major depressive disorder,
is under regulatory review by the FDA. The Company also has a robust pipeline
of follow-on products in both pre-clinical and clinical development.
Labopharm's vision is to become an integrated, international, specialty
pharmaceutical company with the capability to internally develop and
commercialize its own products. For more information, please visit
For further information:
For further information: At Labopharm: Mark D'Souza, Senior
Vice-President and Chief Financial Officer, Tel: (450) 686-0207; At The
Equicom Group: Jason Hogan, Media and Investor Relations, Tel: (416) 815-0700,
firstname.lastname@example.org; French: Joe Racanelli, Tel: (514) 844-7997,